A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
A phase 2/3 trial testing MK-1045 in follicular lymphoma, now recruiting.
Overview
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) is a phase 2/3 interventional study registered as NCT07634471, led by Merck Sharp & Dohme, and recruiting when checked on 2026-09-11. Official title: A Phase 2/3 Randomised, Open-label Study of MK-1045 in Combination With Rituximab in Participants With 1L Follicular Lymphoma. Planned enrolment is 960 participants (estimated). The study started in 2026-06-22 and primary completion is expected in 2032-07-23. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
Shares MK-1045, Merck & Co. (MSD) and the tag ctgov-ingest.
- TrialA Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Shares Merck & Co. (MSD) and the tag ctgov-ingest.
- TrialA Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Shares Merck & Co. (MSD) and the tag ctgov-ingest.
- TrialMK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
Shares Merck & Co. (MSD) and the tag ctgov-ingest.
- TrialA Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
Shares Merck & Co. (MSD) and the tag ctgov-ingest.
- TrialA Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
Shares Merck & Co. (MSD) and the tag ctgov-ingest.
- TrialA Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Shares Merck & Co. (MSD) and the tag ctgov-ingest.
- TrialA Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
Shares Merck & Co. (MSD) and the tag ctgov-ingest.